Literature DB >> 17360557

Haplotype structure and selection of the MDM2 oncogene in humans.

Gurinder Singh Atwal1, Gareth L Bond, Sally Metsuyanim, Moshe Papa, Eitan Friedman, Tal Distelman-Menachem, Edna Ben Asher, Doron Lancet, David A Ross, John Sninsky, Tomas J White, Arnold J Levine, Ronit Yarden.   

Abstract

The MDM2 protein is an ubiquitin ligase that plays a critical role in regulating the levels and activity of the p53 protein, which is a central tumor suppressor. A SNP in the human MDM2 gene (SNP309 T/G) occurs at frequencies dependent on demographic history and has been shown to have important differential effects on the activity of the MDM2 and p53 proteins and to associate with altered risk for the development of several cancers. In this report, the haplotype structure of the MDM2 gene is determined by using 14 different SNPs across the gene from three different population samples: Caucasians, African Americans, and the Ashkenazi Jewish ethnic group. The results presented in this report indicate that there is a substantially reduced variability of the deleterious SNP309 G allele haplotype in all three populations studied, whereas multiple common T allele haplotypes were found in all three populations. This observation, coupled with the relatively high frequency of the G allele haplotype in both and Caucasian and Ashkenazi Jewish population data sets, suggests that this haplotype could have undergone a recent positive selection sweep. An entropy-based selection test is presented that explicitly takes into account the correlations between different SNPs, and the analysis of MDM2 reveals a significant departure from the standard assumptions of selective neutrality.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360557      PMCID: PMC1838634          DOI: 10.1073/pnas.0610998104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  p53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes.

Authors:  Massimiliano Bonafè; Stefano Salvioli; Cristiana Barbi; Michele Mishto; Chiara Trapassi; Claudia Gemelli; Gianluca Storci; Fabiola Olivieri; Daniela Monti; Claudio Franceschi
Journal:  Biochem Biophys Res Commun       Date:  2002-12-13       Impact factor: 3.575

Review 2.  Polymorphic variants in the p53 pathway.

Authors:  M E Murphy
Journal:  Cell Death Differ       Date:  2006-06       Impact factor: 15.828

3.  Two polymorphic variants of wild-type p53 differ biochemically and biologically.

Authors:  M Thomas; A Kalita; S Labrecque; D Pim; L Banks; G Matlashewski
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Narayan Dharel; Naoya Kato; Ryosuke Muroyama; Masaru Moriyama; Run-Xuan Shao; Takao Kawabe; Masao Omata
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

5.  Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.

Authors:  G Bougeard; S Baert-Desurmont; I Tournier; S Vasseur; C Martin; L Brugieres; A Chompret; B Bressac-de Paillerets; D Stoppa-Lyonnet; C Bonaiti-Pellie; T Frebourg
Journal:  J Med Genet       Date:  2005-10-28       Impact factor: 6.318

6.  A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells.

Authors:  Nicoleta C Arva; Tamara R Gopen; Kathryn E Talbott; Latoya E Campbell; Agustin Chicas; David E White; Gareth L Bond; Arnold J Levine; Jill Bargonetti
Journal:  J Biol Chem       Date:  2005-05-20       Impact factor: 5.157

Review 7.  Improving cancer therapy by non-genotoxic activation of p53.

Authors:  S Lain; D Lane
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

8.  p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population.

Authors:  J Shawn Jones; Xuedong Chi; Xiangjun Gu; Patrick M Lynch; Christopher I Amos; Marsha L Frazier
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

9.  Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.

Authors:  Helge Lind; Shanbeh Zienolddiny; Per Olav Ekstrøm; Vidar Skaug; Aage Haugen
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396

10.  Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.

Authors:  Chiara Menin; Maria Chiara Scaini; Gian Luca De Salvo; Martina Biscuola; Monica Quaggio; Giovanni Esposito; Claudio Belluco; Marco Montagna; Simona Agata; Emma D'Andrea; Donato Nitti; Alberto Amadori; Roberta Bertorelle
Journal:  J Natl Cancer Inst       Date:  2006-02-15       Impact factor: 13.506

View more
  30 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 2.  The role of p53 gene family in reproduction.

Authors:  Wenwei Hu
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

3.  Gene Amplifications in Well-Differentiated Pancreatic Neuroendocrine Tumors Inactivate the p53 Pathway.

Authors:  Wenwei Hu; Zhaohui Feng; Ippolito Modica; David S Klimstra; Lin Song; Peter J Allen; Murray F Brennan; Arnold J Levine; Laura H Tang
Journal:  Genes Cancer       Date:  2010-05-15

4.  Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia.

Authors:  Hong Shi; Si-jie Tan; Hua Zhong; Wenwei Hu; Arnold Levine; Chun-jie Xiao; Yi Peng; Xue-bin Qi; Wei-hua Shou; Run-lin Z Ma; Yi Li; Bing Su; Xin Lu
Journal:  Am J Hum Genet       Date:  2009-04-02       Impact factor: 11.025

5.  p53 codon 72 polymorphism and recurrent pregnancy loss: a meta-analysis.

Authors:  Wenru Tang; Xuhong Zhou; Ying Chan; Xiaomin Wu; Ying Luo
Journal:  J Assist Reprod Genet       Date:  2011-08-13       Impact factor: 3.412

6.  Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells.

Authors:  Wanqing Liu; Lijun He; Jacqueline Ramírez; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

7.  Germline mutations and polymorphisms in the origins of cancers in women.

Authors:  Kim M Hirshfield; Timothy R Rebbeck; Arnold J Levine
Journal:  J Oncol       Date:  2010-01-10       Impact factor: 4.375

8.  Fine-scale detection of population-specific linkage disequilibrium using haplotype entropy in the human genome.

Authors:  Hideaki Mizuno; Gurinder Atwal; Haijian Wang; Arnold J Levine; Alexei Vazquez
Journal:  BMC Genet       Date:  2010-04-23       Impact factor: 2.797

9.  Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene.

Authors:  Gurinder Singh Atwal; Tomas Kirchhoff; Elisabeth E Bond; Marco Montagna; Marco Monagna; Chiara Menin; Roberta Bertorelle; Maria Chiara Scaini; Frank Bartel; Anja Böhnke; Christina Pempe; Elise Gradhand; Steffen Hauptmann; Kenneth Offit; Arnold J Levine; Gareth L Bond
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-04       Impact factor: 11.205

10.  Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations.

Authors:  Hovav Nechushtan; Tamar Hamburger; Susan Mendelson; Luna Kadouri; Nir Sharon; Eli Pikarsky; Tamar Peretz
Journal:  BMC Cancer       Date:  2009-02-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.